Prolia (denosumab) does increase bone density. Prolia works by targeting a molecule called RANKL that osteoclasts need to work. By stopping RANKL from binding to its receptor Prolia reduces bone breakdown, bone loss, bone pain, and other bone complications. BMD was increased by 8.8% at the lumbar spine, 6.4% at the total hip, and 5.2% at the femoral neck in trials that measured BMD after three years of treatment with Prolia.